Extensive cytoreductive surgery in advanced ovarian carcinoma

European Journal of Gynaecological Oncology

Volumn 18, Issue 1, 1997, Pages 9-15

  Michel, G ^a   De Iaco, P ^a   Castaigne, D ^a   El Hassan, M J ^a   Lobreglio, R ^a   Lhomme C ^a   Rey, A ^a   Duvillard, P ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Morbidity; Ovarian carcinoma; Prognosis; Residual tumor; Surgery

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ABDOMINAL HYSTERECTOMY; ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LAPAROTOMY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR; SALPINGOOOPHORECTOMY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; POSTOPERATIVE COMPLICATIONS; SURVIVAL RATE;

EID: 0031045213     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Wils A.: "Long-tem follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin doxorubicin, and cyclophosphamide". Oncology, 1990, 47, 115.
2. Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E. L. et al.: "Long-term survival in ovarian cancer". Eur. J. Cancer, 1991, 27, 1367.
3. Goodman H. M., Harlow B. L., Sheets E. E. et al.: "The role of cytoreductive surgery in the management of Stage IV epithelial ovarian carcinoma". Gynecol Oncol;, 1992, 46, 367.
4. Venesmaa P.: "Epithelial ovarian cancer: impact of surgery and chemotherapy on survival during 1977-1990". Obstet. Gynecol., 1994, 84, 8.
5. Griffiths C. T., Parker L. M., Fuller A. F jr: "Role of cytoreductive surgical treatment in the management of advanced ovarian cancer". Cancer Treat. Rep., 1979, 63, 235.
6. Hacker N. F., van der Burg M. E. L.: "Debulking and intervention surgery". Ann. Oncol., 1993, 4 (Suppl. 4), S17.
7. Potter M. E., Partridge E. E., Hatch K. D., Soong S. J., Austin J. M., Shingleton H. M.: "Primary surgical therapy of ovarian cancer: how much and when". Gynecol. Oncol., 1991, 40, 195.
8. International Federation of Gynecology and Obstetrics. Annual report on the results of treatment in gynecological cancer". Int. J. Gynecol. Obstet., 1989, 28, 189.
9. Michel G., Castaigne D., Zarca D. D.: "Chirurgie des tumeurs malignes de l'ovaire". Encycl. Méd. Chir., 1993, 41, 1.
10. Michel G., Castaigne D., Lhommé C., Duvillard P.: "Value of supraradical surgery in advanced ovarian cystadenocarcinomas (abstract)". Eur. J. Clin. Oncol., 1993, 29A, (727), S133.
11. Heintz A. P. M., Hacker N. F., Berek J. S. et al.: "Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity". Obstet. Gynecol, 1986, 67, 783.
12. Venesmaa P., Ylikorkala O.: "Morbidity and mortality associated with primary and repeat operations for ovarian cancer". Obstet. Gynecol., 1992, 79, 168.
13. Bridges J. E., Leung Y., Hammond I. G., McCartney A. J.: "En bloc resection of epithelial ovarian tumors with concomitant rectosigmoid colectomy: the KEMH experience". Int. J. Gynecol. Cancer, 1993, 3, 199.
14. Morris M., Gershenson D. M., Burke T. W., Wharton J. T., Copeland L. J., Rutledge F. N.: "Splenectomy in gynecologic oncology: indications, complications, and technique". Gynecol. Oncol , 1991, 43, 118.
15. Donato D., Angelides A., Irani H., Penalver M., Averette H.: "Infectious complications after gastrointestinal surgery in patients with ovarian carcinoma and malignant ascites". Gynecol. Oncol., 1992, 44, 40.
16. Eisenkop S. M., Nalick R. H., Wang H., Teng N. N. H.: "Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival". Gynecol. Oncol., 1993, 51, 224.
17. Unzelman R. F.: "Advanced epithelial ovarian carcinoma: long-term survival experience at the community hospital". Am. J. Obstet. Gynecol., 1992, 166, 1663.
18. Gruppo Interregionale Cooperativo Oncologico Ginecologia. "Randomized comparison of cisplatin with cyclophosphamide / cisplatin and with cyclophosphamide / doxorubicin / cisplatin in advanced ovarian cancer". Lancet, 1987, ii, 353.
19. Editorial. "Ovarian cancer: any progress?". Ann. Oncol., 1993, 4, 264.
20. Levi F., Franceschi S., La Vecchia C. et al.: "Epidemiologic pathology of ovarian cancer from the Vaud cancer registry Switzerland". Ann. Oncol., 1993, 4 (4), 289.
21. Barber H. R. K.: "An update on diagnosis and management of advanced ovarian cancer". Eur. J. Gynaecol. Oncol., 1991, 12 (Suppl.), 252.
22. Guidozzi F., Ball J. H. S.: "Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer". Gynecol. Oncol., 1994, 53, 326.
23. Griffiths C. T., Fuller A. F.: "Intensive surgical and chemotherapeutic management of advanced ovarian cancer". Symposium on gynaecological cancer". Surg. Clin. North. Am., 1978, 55, (1), 131.
24. Hacker N. F., Jonathan S. B., Lagasse L. D., Nieberg R. K., Elashoff R. M.: "Primary cytoreductive surgery for epithelial ovarian cancer". Obstet. Gynecol., 1983, 61, 413.
25. Piver M. S., Lele S. B., Marchetti D. L., Baker T. R., Tsukada Y., Emrich L. J.: "The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in Stage III and IV ovarian carcinoma". J. Clin. Oncol., 1988, 6, 983.
26. Bertelsen K.: "Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study". Gynecol. Oncol., 1990, 38, 203.
27. Fontanelli R., Paladini D., Raspagliesi F., di Re E.: "The role of appendectomy in surgical procedures for ovarian cancer". Gynecol. Oncol., 1992, 46, 42.
28. Berek J. S., Hacker N. F., Lagasse L. D., Leuchter R. S.: "Lower urinary tract resection as part of cytoreductive surgery for ovarian cancer". Gynecol. Oncol., 1982, 13, 87.
29. Chen S. S., Lee L.: "Incidence or para-aortic and pelvic lymph node metastases in epithelial carcinoma of the ovary: feasibility and morbidity". Gynecol. Oncol., 1991, 40, 95.
30. Kigawa J., Minagawa Y., Ishihara H , Kanamori Y., Itamochi H., Terakawa N.: "Evaluation of cytoreductive surgery with lymphadenectomy including para-aortic nodes for advanced ovarian cancer". Eur. J. Surg. Oncol., 1993, 19, 273.
31. Burgjardt E., Winter R.: "The effect of chemotherapy on lymph node metastases in ovarian cancer". Baillière's Clin. Obstet. Gynecol., 1989, 3, 157.
32. Baker T. R., Piver M. S., Hempling R. E.: "Long-term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma". Cancer, 1994, 74, 656.
33. Del Campo J. M., Felip E., Rubio D. et al.: "Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment". Gynecol. Oncol., 1994, 53, 27.
34. Hoskins W. J., McGuire W. P., Brady M. F. et al.: "The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma". Am. J. Obstet. Gynecol., 1994, 170, 974.
35. Omura G. A., Brady M. F., Homesley H. D. et al.: "Long follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience". J. Clin. Oncol., 1991, 9, 1138.
36. Griffiths C. T., Fuller A. F.: "Intensive surgical and chemotherapy management of advanced ovarian cancer". Surg. Clin. North. Am., 1978, 58, 131.
37. Heintz A. P. M., van Oosterom A. T., Trimbos J. B. et al.: "The treatment of advanced ovarian carcinoma (1): clinical variables associated with prognosis". Gynecol. Oncol., 1988, 30, 347.
38. Hunter R. W., Alexander N. D. E., Soutter W. P.: "Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?". Am. J. Obstet. Gynecol., 1992, 166, 504.
39. Levin L., Lund B., Heintz A. P. M.: "An overview of multivariate analyses of prognostic variables with special references to the role of cytoreductive surgery". Ann. Oncol., 1993, 4, (Suppl. 4), S23.
40. Kayes S. B., van Houwelingen H. C.: "What have we learnt from meta-analyses in ovarian cancer?". Ann. Oncol., 1993, 4 (Suppl. 4), S79.
41. Schzartz P. E., Chambers J. T., Makuch R.: "Neoadjuvant chemotherapy for advanced ovarian cancer". Gynecol. Oncol., 1994, 53, 33.
42. Van der Burg M. E. L., van Lent M., Kobierska A. et al.: "Intervention debulking surgery (IDS) dos improve survival in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study". Proc. ASCO, 1993, 12 (818), 258.
43. Camilio S. M.: "Plasminogen activator content of gynecological tumors and their metastasis". Gynecol. Oncol., 1987, 26, 364.
44. Karlan B., Amin W.: "Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro". Gynecol. Oncol., 1988, 31, 103.
45. Seifter E. J.: "Coagulation abnormalities in patients with cancer". Clin. Oncol., 1983, 12, 657.
46. Siegman I., Gray Y.: "Chronic diffuse intravascular coagulation in non-metastatic ovarian cancer". Gynecol. Oncol., 1977, 5.
47. Blythe J. G., Wahl T. P.: "Debulking surgery: does it increase the quality of survival?", Gynecol. Oncol., 1982, 14, 396.